Evidence map›Paper›PMID 32418004›Full record

ArticleInflammopharmacology2020

Baicalein exerts neuroprotective effect against ischaemic/reperfusion injury via alteration of NF-kB and LOX and AMPK/Nrf2 pathway.

Yu Yuan, Weidong Men, Xiaosong Shan, Hexin Zhai, Xiaoxia Qiao, Lianting Geng, Chunhui Li

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Therapeutic Effects ofLife (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Effects of lercanidipine on traumatic spinal cord injury: an experimental study.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yu YuanNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Weidong MenNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Xiaosong ShanNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Hexin ZhaiEmergency Department, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Xiaoxia QiaoNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Lianting GengNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Chunhui LiNeurosurgery, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China. lichunhui0860312@sina.com.ORCID http://orcid.org/0000-0001-8365-5878
Affiliated Hospital of Hebei University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ischaemic stroke accounts for almost 11% of all deaths worldwide and has a high incidence of permanent disability among patients. Baicalein has many beneficial pharmacological properties, including anti-inflammatory and anti-oxidant effects. However, the neuroprotective effect of baicalein is still unclear. The current study scrutinizes the neuroprotective effect of baicalein against the ischaemic/reperfusion (I/R) injury via alteration of the nuclear factor kappa B (NF-kB) and AMP-activated protein kinase/nuclear factor erythroid 2-related factor 2 AMPK/Nrf2 signaling pathway. Wistar rats were used for the current study. In rats, I/R injury was caused by transient occlusion of the middle cerebral artery for 1 h accompanied by reperfusion for 24 h. The rats were divided into different groups and treated with the different doses of baicalein (2.5, 5 and 10 mg/kg). The effects of baicalein on the murine neurological function were determined via infarct volume, neurological defect scores, and brain water content. The -inflammatory cytokines and oxidative stress were estimated in the region of the cortical along with the expression of apoptosis markers, such as B-cell lymphoma 2, Bax, and caspase-3. Quantitative reverse transcription polymerase chain reaction was used for the estimation of the NF-kB, cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression. Baicalein significantly (p < 0.001) ameliorated the infarction volume, brain water content, and neurological outcome, and the malondialdehyde level, and reduced the level of interleukin-1β, interleukin-6, tumor necrosis factor-α, superoxide dismutase, glutathione, and catalase in a dose-dependent manner. Baicalein significantly (p < 0.001) altered the expression of COX-2, PGE2, LOX-1 and NF-kB as compared to I/R control group rats. Baicalein significantly reduced the Nrf2 and AMPK levels, and protected the rat brain against the I/R injury, suggesting a neuroprotective effect via down-regulation of NF-kB and LOX-1 expression and the AMPK/Nrf2 pathway.

Indexed as

AMP-Activated Protein KinasesAnimalsCell Line, TumorDose-Response Relationship, DrugFlavanonesHumansIschemic StrokeMaleNeuroprotective AgentsNF-E2-Related Factor 2NF-kappa BOxidative StressRatsRats, WistarReperfusion InjuryScavenger Receptors, Class EAMP-Activated Protein KinasesbaicaleinFlavanonesNeuroprotective AgentsNfe2l2 protein, ratNF-E2-Related Factor 2NF-kappa BOLR1 protein, ratScavenger Receptors, Class EAMPK/Nrf2 pathwayBaicaleinCOX-2InflammationI/R ratNF-kBOxidative stress

Identifiers

PMID32418004
OpenAlexW3025820408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.